Immunology of infants through adolescents: Responses to emulate for HIV vaccines

Current Opinion in HIV and AIDS

Volumn 2, Issue 5, 2007, Pages 391-398

  Jaspan, Heather B ^a,b   Hanekom, Willem A ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Adolescents; HIV; Immunology; Infants; Vaccines

Indexed keywords

DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MATERNAL ANTIBODY; NEUTRALIZING ANTIBODY;

CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; PREVENTION AND CONTROL; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; STATISTICAL SIGNIFICANCE;

EID: 34547891567     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282e1c633     Document Type: Review

References (104)

1. UNAIDS. EpiUpdate 2006; Geneva: UNAIDS; 2006.
2. Lambert JS. HIV vaccines in infants and children. Paediatr Drugs 2005; 7:267-276.
3. Safrit JT. HIV vaccines in infants and children: Past trials, present plans and future perspectives. Curr Mol Med 2003; 3:303-312.
4. Jaspan HB, Lawn SD, Safrit JT, et al. The maturing immune system: implications for development and testing HIV-1 vaccines for children and adolescents. AIDS 2006; 20:483-494. This is an extensive review of the immune system of infants and the effects of puberty on immunology. In addition, examples of differing responses to known vaccines in infants and adolescents are discussed.
5. Koup RA, Safrit JT, Cao YZ, et al. Temporal association of cellular immuneresponses with the initial control of viremia in primary human-immunodeficiency-virus type-1 syndrome. J Virol 1994; 68:4650-4655.
6. Safrit JT, Ruprecht R, Ferrantelli F, et al. Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr 2004; 35:169-177.
7. Geels MJ, Jansen CA, Baan E, et al. CTL escape and increased viremia irrespective of HIV-specific CD4(+) T-helper responses in two HIV-infected individuals. Virology 2006; 345:209-219.
8. Karlsson AC, Iverson AK, Chapman JM, et al. Sequential Broadening of CTL Responses in Early HIV-1 Infection Is Associated with Viral Escape. PLoS ONE 2007; 2:e225.
9. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-1671.
10. Flynn MN, Forthal DN, Harro CD, et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191:654-665.
11. McBurney SP, Young KR, Ross TM. Membrane embedded HIV-1 envelope on the surface of a virus-like particle elicits broader immune responses than soluble envelopes. Virology 2007; 358:334-346.
12. Derby NR, Kraft Z, Kan E, et al. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: Comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J Virol 2006; 80:8745-8762. This preclinical study evaluated various gp140 proteins aimed at inducing broadly neutralizing antibodies. These immunogens did not elicit as broad a response as hoped, and certainly narrower than that of natural infection. This may be due to the predominance of V1-directed antibodies.
13. Kumar S, Yan J, Muthumani K, et al. Immunogenicity testing of a novel engineered HIV-1 envelope Gp140 DNA vaccine construct. DNA Cell Biol 2006; 25:383-392.
14. Bower JF, Li YX, Wyatt R, et al. HIV-1 Env(gp140) trimers elicit neutralizing antibodies without efficient induction of conformational antibodies. Vaccine 2006; 24:5442-5451.
15. Pantophlet R, Burton DR. GP120: Target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006; 24:739-769.
16. Zhou TQ, Xu L, Dey B, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007; 445:732-737.
17. Zhang MY, Shu Y, Sidorov I, et al. Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades. Antiviral Res 2004; 61:161-164.
18. Calarese DA, Lee HK, Huang CY, et al. Dissection of the carbohydrate specificity of the broadly neutralizing-anti-HIV-1 antibody 2G12. Proc Natl Acad Sci U S A 2005; 102:13372-13377.
19. Jiang PF, Liu YX, Yin XL, et al. Elicitation of neutralizing antibodies by intranasal administration of recombinant vesicular stomatitis virus expressing human immunodeficiency virus type 1 gp120. Biochem Biophys Res Commun 2006; 339:526-532. This is a report of a novel mucosal HIV vaccine that has the potential to stimulate excellent broad immune responses in neonates.
20. Ni JH, Song HJ, Wang YD, et al. Toward a carbohydrate-based HIV-1 vaccine: Synthesis and immunological studies of oligomannose-containing glycoconjugates. Bioconjug Chem 2006; 17:493-500.
21. Wang LX. Toward oligosaccharide- and glycopeptide-based HIV vaccines. Curr Opin Drug Discov Devel 2006; 9:194-206.
22. Spearman P. Current progress in the development of HIV vaccines. Curr Pharm Des 2006; 12:1147-1167. This is an extensive review of the current state of HIV vaccine development and testing.
23. Mattapallil JJ, Douek DC, Buckler-White A, et al. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med 2006; 203:1533-1541.
24. Letvin NL, Mascola JR, Sun Y, et al. Preserved CD4(+) central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 2006; 312:1530-1533.
25. Ellenberger D, Otten RA, Li B, et al. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology 2006; 352:216-225. This study showed that, with inocula more closely resembling those encountered during sexual exposure, a DNA prime MVA boost does reduce the per-challenge risk of macaque SHIV infection, giving renewed hope for current T-cell-based vaccines.
26. Wright PF, Mestecky J, McElrath MJ, et al. Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. J Infect Dis 2004; 189:1221-1231.
27. Vajdy M. Current efforts on generation of optimal immune responses against HIV through mucosal immunisations. Drugs R D 2006; 7:267-288.
28. Musey L, Ding Y, Elizaga A, et al. HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals. J Immunol 2003; 171:1094-1101.
29. Egan MA, Chong SY, Hagen M, et al. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques. Vaccine 2004; 22:3774-3788.
30. Vajdy M, Gupta S, Polo J. Enhancement of antibody responses against HIV in rhesus macaques following combinations of mucosal and systemic immunizations with chimeric vs. complete alphavirus-based replicon particles. J Immunol 2006; 176:S245.
31. Lambert PH, Liu M, Siegrist CA. Can successful vaccines teach us how to induce efficient protective immune responses? Nat Med 2005; 11:S54-S62.
32. Landers CD, Chelvarajan RL, Bondada S. The role of B cells and accessory cells in the neonatal response to TI-2 antigens. Immunol Res 2005; 31:25-36.
33. Decker MD, Edwards KM, Bradley R, et al. Comparative trial in infants of 4 conjugate haemophilus-influenzae type-B vaccines. J Pediatr 1992; 120:184-189.
34. Borkowsky W, Wara D, Fenton T, et al. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. J Infect Dis 2000; 181:890-896.
35. Johnson DC, McFarland EJ, Muresan P, et al. Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1 infected women. J Infect Dis 2005; 192:2129-2133.
36. McFarland EJ, Johnson DC, Muresan P, et al. HIV-1 vaccine induced immune responses in newborns of HIV-1 infected mothers. AIDS 2006; 20:1481-1489. Although this vaccination schedule induced weak responses in these HIV-exposed infants immunized with the recombinant canarypox HIV vaccines, studies such as these are vital steps toward finding a neonatal HIV vaccine. In addition, the study explored the effects of maternal antibody on vaccine immunogenicity.
37. McFarland EJ, Borkowsky W, Fenton T, et al. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J Infect Dis 2001; 184:1331-1335.
38. van Rooij EMA, Moonen-Leusen HW, de Visser YE, et al. A DNA vaccine coding for gB and gD of pseudorabies virus (suid herpes type 1) primes the immune system in the presence of maternal immunity more efficiently than conventional vaccines. Vaccine 2006; 24:1264-1273. This is a study of DNA vaccination for rabies in mice, showing that DNA priming is effective at overcoming maternal passive antibody.
39. Wang YJ, Xiang ZQ, Pasquini S, et al. Effect of passive immunization or maternally transferred immunity on the antibody response to a genetic vaccine to rabies virus. J Virol 1998; 72:1790-1796.
40. Thorner AR, Vogels R, Kaspers J, et al. Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa. J Clin Microbiol 2006; 44:3781-3783.
41. Thorner AR, Lemckert AAC, Goudsmit J, et al. Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J Virol 2006; 80:12009-12016.
42. Lemiale F, Haddada H, Nabel GJ, et al. Novel adenovirus vaccine vectors based on the enteric-tropic serotype 41. Vaccine 2007; 25:2074-2084.
43. Egan MA, Chong SY, Rose NF, et al. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 env and SIV Gag proteins: Comparison of intranasal and intramuscular vaccination routes. AIDS Res Hum Retroviruses 2004; 20:989-1004.
44. Hesseling AC, Marais BJ, Gie RP, et al. The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children. Vaccine 2007; 25:14-18.
45. De Magistris MT. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Deliv Rev 2006; 58:52-67. This is an extensive review of the methods to induce mucosal immunity in children.
46. Nurkka A, Joensuu D, Henckaerts I, et al. Immunogenicity and safety of the eleven valent pneumococcal polysaccharide-protein D conjugate vaccine in infants. Pediatr Infect Dis J 2004; 23:1008-1014.
47. Ranasinghe C, Medveczky JC, Woltring D, et al. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1. Vaccine 2006; 24:5881-5895.
48. Crotty S, Miller CJ, Lohman BL, et al. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J Virol 2001; 75:7435-7452.
49. Tsunetsugu-Yokota Y, Ishige M, Murakami M. Oral attenuated Salmonella enterica serovar typhimurium vaccine expressing codon-optimized HIV type 1 Gag enhanced intestinal immunity in mice. AIDS Res Hum Retroviruses 2007; 23:278-286.
50. Young KR, McBurney SP, Karkhanis LU, et al. Virus-like particles: Designing an effective AIDS vaccine. Methods 2006; 40:98-117.
51. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-1651.
52. Villa LL, Perez G, Kjaer SK, et al. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356:1915-1927.
53. Matoba N, Geyer BC, Kilbourne J, et al. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR649-684, a mucosal subunit HIV/AIDS vaccine candidate. Vaccine 2006; 24:5047-5055.
54. Devito C, Zuber B, Schroder U, et al. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J Immunol 2004; 173:7078-7089.
55. Coovadia HM, Rollins NC, Bland RM, et al. Mother-to-child transmission of HIV-1 infection during exclusive breastfeeding in the first 6 months of life: an intervention cohort study. Lancet 2007; 369:1107-1116. This large study demonstrated that even in the presence of excusive breastfeeding with abrupt cessation, with a labor-intensive intervention to support infant feeding choices, HIV transmission is high, and an HIV vaccine that protects neonates from breast milk HIV exposure is urgently needed.
56. Thior I, Lockman S, Smeaton LM, et al. Breastfeeding plus infant zidovudine prophylaxis for 6 months vs formula feeding plus infant zidovudine for 1 month to reduce mother-to-child HIV transmission in Botswana. A randomized trial: The Mashi study. JAMA 2006; 296:794-805.
57. Mbori-Ngacha D, Nduati R, John G, et al. Morbidity and mortality in breastfed and formula-fed infants of HIV-1-infected women: A randomized clinical trial. JAMA 2001; 286:2413-2420.
58. Lu L, Mach O, Creek T, et al. Community use and impact of a supplemental weaning food during a diarrhea and malnutrition outbreak - Botswana, 2006. Am J Trop Med Hyg 2006; 75:128.
59. Velilla PA, Rugeles MT, Chougnet CA. Defective antigen-presenting cell function in human neonates. Clin Immunol 2006; 121:251-259.
60. Janeway CA, Travers P, Walport M, et al. Immunobiology: The Immune System in Health and Disease. 6th ed. New York: Garland; 2004.
61. Premenko-Lanier M, Hodge G, Rota P, et al. Matemal antibody inhibits both cellular and humoral immunity in response to measles vaccination at birth. Virology 2006; 350:429-432.
62. Premenko-Lanier M, Rota PA, Rhodes GH, et al. Protection against challenge with measles virus (MV) in infant macaques by an MV DNA vaccine administered in the presence of neutralizing antibody. J Infect Dis 2004; 189:2064-2071.
63. Hassan J, Reen DJ. T-cell function in the human newborn. Immunol Today 2000; 21:107-108.
64. Marchant A, Goetghebuer T, Ota MO, et al. Newborns develop a Th1-type immune response to Mycobacterium bovis Bacillus Calmette-Guerin vaccination. J Immunol 1999; 163:2249-2255.
65. Scott ZA, Chadwick EG, Gibson LL, et al. Infrequent detection of HIV-1-specific, but not cytomegalovirus-specific, CD8(+) T cell responses in young HIV-1-infected infants. J Immunol 2001; 167:7134-7140.
66. Sanchez-Merino V, Nie SW, Luzuriaga K. HIV-1-specific CD8(+) T cell responses and viral evolution in women and infants. J Immunol 2005; 175:6976-6986.
67. Embree JE, Njenga S, Datta P, et al. Risk factors for postnatal mother-child transmission of HIV-1. AIDS 2000; 14:2535-2541.
68. Newburg DS, Walker WA. Protection of the neonate by the innate immune system of developing gut and of human milk. Pediatr Res 2007; 61:2-8.
69. Abel K, Pahar B, Van Rompay KKA, et al. Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses. J Virol 2006; 80:6357-6367. This study showed the 4-week-old infant macaque response to simian immunodeficiency virus infection at mucosal and distant sites. Importantly, proinflammatory (IFNγ) responses were observed at the tonsils and other local sites.
70. Abel K, Rocke DM, Chohan B, et al. Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol 2005; 79:12164-12172.
71. Crespo I, Paiva A, Couceiro A, et al. Immunophenotypic and functional characterization of cord blood dendritic cells. Stem Cells Dev 2004; 13:63-70.
72. Holt PG. Dendritic cell ontogeny as an aetiological factor in respiratory tract diseases in early life. Thorax 2001; 56:419-420.
73. Tschernig T, de Vries VC, Debertin AS, et al. Density of dendritic cells in the human tracheal mucosa is age dependent and site specific. Thorax 2006; 61:986-991.
74. Tschernig T, Debertin AS, Paulsen F, et al. Dendritic cells in the mucosa of the human trachea are not regularly found in the first year of life. Thorax 2001; 56:427-431.
75. Van Rie A, Madhi SA, Heera JR, et al. Gamma interferon production in response to Mycobacterium bovis BCG and Mycobacterium tuberculosis antigens in infants born to human immunodeficiency virus-infected mothers. Clin Vaccine Immunol 2006; 13:246-252. This was an important study of the immunogenicity of vaccines in infants born to HIV-infected mothers, and showed that even HIV exposure profoundly affects infants' immune responses. This is important as many of our HIV vaccinees will be HIV-exposed and this will affect the immunogenicity of any vaccine.
76. Mussi-Pinhata MM, Freimanis L, Yamamoto AY, et al. Infectious disease morbidity among young HIV-1 exposed but uninfected infants in Latin American and Caribbean countries: The National Institute of Child Health and Human Development International Site Development Initiative Perinatal Study. Pediatrics 2007; 119:E694-E704.
77. McNally LM, Jeena PM, Gajee K, et al. Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study. Lancet 2007; 369:1440-1451.
78. Kuhn L, Kasonde P, Sinkala M, et al. Does severity of HIV disease in HIV-infected mothers affect mortality and morbidity among their uninfected infants? Clin Infect Dis 2005; 41:1654-1661.
79. Stiehm ER, Lambert JS, Mofenson LM, et al. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: Results of pediatric AIDS clinical trials group protocol 185. J Infect Dis 1999; 179:567-575.
80. Guay LA, Musoke P, Hom DL, et al. Phase I/II trial of HIV-1 hyperimmune globulin for the prevention of HIV-1 vertical transmission in Uganda. AIDS 2002; 16:1391-1400.
81. Ferrantelli F, Hofmann-Lehmann R, Rasmussen RA, et al. Postexposure prophylaxis with human monoclonal antibodies prevented SHIV89.6P infection or disease in neonatal macaques. AIDS 2003; 17:301-309.
82. Van Rompay KKA, Abel K, Lawson JR, et al. Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquir Immune Defic Syndr 2005; 38:124-134.
83. Kanda N, Tamaki K. Estrogen enhances immunoglobulin production by human PBMCs. J Allergy Clin Immunol 1999; 103:282-288.
84. Jiang XG, Orr BA, Kranz DM, et al. Estrogen induction of the granzyme B inhibitor, proteinase inhibitor 9, protects cells against apoptosis mediated by cytotoxic T lymphocytes and natural killer cells. Endocrinology 2006; 147:1419-1426.
85. Shrier LA, Bowman FP, Lin M, et al. Mucosal immunity of the adolescent female genital tract. J Adolesc Health 2003; 32:183-186.
86. Jones RK, Bulmer JN, Searle RF. Cytotoxic activity of endometrial granulated lymphocytes during the menstrual cycle in humans. Biol Reprod 1997; 57:1217-1222.
87. Sakakura Y, Nakagawa Y, Ohzeki T. Differential effect of DHEA on mitogen-induced proliferation of T and B lymphocytes. J Steroid Biochem Mol Biol 2006; 99:115-120.
88. Dillon JS. Dehydroepiandrosterone, dehydroepiandrosterone sulfate and related steroids: their role in inflammatory, allergic and immunological disorders. Curr Drug Targets Inflamm Allergy 2005; 4:377-385.
89. Ramonet M, da Silveira TR, Lisker-Melman M, et al. A two-dose combined vaccine against hepatitis A and hepatitis B in healthy children and adolescents compared to the corresponding monovalent vaccines. Arch Med Res 2002; 33:67-73.
90. Cassidy WM, Watson B, Ioli VA, et al. A randomized trial of alternative two- and three-dose hepatitis B vaccination regimens in adolescents: Antibody responses, safety, and immunologic memory. Pediatrics 2001; 107:626-631.
91. Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118:2135-2145. This is a report of the key immunogenicity study that bridges immunogenicity of the human papilloma virus vaccine to preadolescents. Additionally, immunogenicity in young males is demonstrated. The study also provided a demonstration of how bridging can be achieved once a surrogate marker of protection is identified.
92. Stanberry LR, Spruance SL, Cunningham AL, et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N Engl J Med 2002; 347:1652-1661.
93. Barratt-Boyes SM, Soloff AC, Gao WT, et al. Broad cellular immunity with robust memory responses to simian immunodeficiency virus following serial vaccination with adenovirus 5-and 35-based vectors. J Gen Virol 2006; 87:139-149. In this macaque model, heterologous prime-boosting with adenovirus 35-based vectors after Ad5 priming overcomes the preexisting immunity that attenuates the response to homologous prime-boosting.
94. Santra S, Seaman MS, Xu L, et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 2005; 79:6516-6522.
95. Roberts DM, Nanda A, Havenga MJE, et al. Hexon-chimaeric adenovirus serotype 5 vectors circumvent preexisting antivector immunity. Nature 2006; 441:239-243.
96. Landers CD, Bondada S. CpG oligodeoxynucleotides stimulate cord blood mononuclear cells to produce immunoglobulins. Clin Immunol 2005; 116:236-245.
97. Johansen K, Schroder U, Svensson L. Immunogenicity and protective efficacy of a formalin-inactivated rotavirus vaccine combined with lipid adjuvants. Vaccine 2003; 21:368-375.
98. Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006; 194:1638-1649. This describes a challenge experiment in macaques using the current adenoviral vector in phase IIb testing. Escape from control of viremia is demonstrated, implying that certain T-cell-based HIV vaccines such as this one may be disappointing.
99. Casimiro DR, Wang FB, Schleif WA, et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005; 79:15547-15555.
100. Wilson NA, Reed J, Napoe GS, et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 2006; 80:5875-5885.
101. Murray RA, Mansoor N, Harbacheuski R, et al. Bacillus Calmette Guerin vaccination of human newborns induces a specific, functional CD8+ T cell response. J Immunol 2006; 177:5647-5651. This is an elegant demonstration of the ability of neonates to mount adult-like T-cell responses when the right immunogen is used.
102. Hanekom WA. The immune response to BCG vaccination of newborns. Ann N Y Acad Sci 2005; 1062:69-78.
103. Mascart F, Hainaut M, Peltier A, et al. Modulation of the infant immune responses by the first pertussis vaccine administrations. Vaccine 2007; 25:391-398. This is an excellent example of the ability to modulate the infant immune response by adapting the priming vaccine. This effect is important to bear in mind that HIV vaccination at birth may affect responses to vaccines given later on in infancy.
104. Piedra PA, Gaglani MJ, Riggs M, et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 2005; 116:E397-E407.